source
- Pediatric rare cancer research draws steady investment despite biotech market volatilityThe article notes that pediatric rare cancers continue to attract investment because they address the greatest unmet medical needs and allow clear measurement of patient impact. Even as the biotec…
- Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureInvestors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.BioSpace · 2h ago↗ source
- Moderna shares surge as Merck-Moderna mRNA melanoma vaccine meets Phase 3 endpoint